icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
mmWZfGNkS9dEzDzP
Listen
